secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001104659-25-028830
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte CEO rebuts NYT article questioning FDA approval of Symvess
-------------------------------------------------------------------

- FDA took 19 extra weeks after PDUFA date, consulted three outside surgeons before approving Symvess on Dec 19, 2024.
- Dr. Lee, cited as source, resigned from FDA months before approval; his LinkedIn says he 'retired' after a decade.
- CEO disputes claim synthetic grafts never rupture; cites MAUDE database showing >25% failures from rupture/death.
- In Ukrainian wartime study, all Symvess-treated limbs retained at 30 days with zero infections.
- Post-approval study planned to confirm safety; prior studies on 600+ patients never halted for safety.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000110465925028830/0001104659-25-028830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000110465925028830/tm2510708d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-028830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer